Page 621 - Basic _ Clinical Pharmacology ( PDFDrive )

CHAPTER 33 Agents Used in Cytopenias; Hematopoietic Growth Factors 607

PREP AR A TIONS REFERENCES
A V AIL ABLE Aapro MS et al, European Organisation for Research and Treatment of Cancer:
2010 update of EORTC guidelines for the use of granulocyte-colony
stimulating factor to reduce the incidence of chemotherapy-induced febrile
GENERIC NAME AVAILABLE AS neutropenia in adult patients with lymphoproliferative disorders and solid
Darbepoetin alfa Aranesp tumours. Eur J Cancer 2011;47:8.
Deferasirox Exjade Albaramki J et al: Parenteral versus oral iron therapy for adults and children with
chronic kidney disease. Cochrane Database Syst Rev 2012;(1):CD007857.
Deferoxamine Generic, Desferal Auerbach M, Al Talib K: Low-molecular weight iron dextran and iron sucrose
Eltrombopag Promacta have similar comparative safety profiles in chronic kidney disease. Kidney
Epoetin alfa Erythropoietin (EPO), Epogen, Int 2008;73:528.
Procrit Barzi A, Sekeres MA: Myelodysplastic syndromes: A practical approach to diagno-
Epoetin beta (Methoxy Mircera sis and treatment. Cleve Clin J Med 2010;77:37.
polyethylene glycol–epoetin beta) Brittenham GM: Iron-chelating therapy for transfusional iron overload. N Engl J
Med 2011;364:146.
Filgrastim (G-CSF) Neupogen, Granix
Clark SF: Iron deficiency anemia: diagnosis and management. Curr Opin Gastro-
Folic acid (folacin, pteroylglutamic Generic enterol 2009;25:122.
acid) Darshan D, Fraer DM, Anderson GJ: Molecular basis of iron-loading disorders.
Iron Expert Rev Mol Med 2010;12:e36.
Oral: See Table 33–3. Gertz MA: Current status of stem cell mobilization. Br J Haematol 2010;150:647.
Iron dextran (parenteral) INFeD, Dexferrum Kessans MR, Gatesman ML, Kockler DR: Plerixafor: A peripheral blood stem cell
Sodium ferric gluconate Ferrlecit mobilizer. Pharmacotherapy 2010;30:485.
complex (parenteral) McKoy JM et al: Epoetin-associated pure red cell aplasia: Past, present, and future
considerations. Transfusion 2008;48:1754.
Iron sucrose (parenteral) Venofer
Rees DC, Williams TN, Gladwin MT: Sickle-cell disease. Lancet 2010;376:2018.
Ferric carboxymaltose Injectafer Rizzo JD et al: American Society of Clinical Oncology/American Society of Hema-
(parenteral) tology clinical practice guideline update on the use of epoetin and darbepo-
Ferumoxytol (parenteral) Feraheme etin in adult patients with cancer. J Clin Oncol 2010;28:4996.
Oprelvekin (IL-11) Neumega Sauer J, Mason JB, Choi SW: Too much folate: A risk factor for cancer and cardio-
Pegfilgrastim Neulasta vascular disease? Curr Opin Clin Nutr Metab Care 2009;12:30.
Plerixafor Mozobil Solomon LR: Disorders of cobalamin (vitamin B12) metabolism: Emerging con-
cepts in pathophysiology, diagnosis and treatment. Blood Rev 2007;21:113.
Romiplostim Nplate Stasi R et al: Thrombopoietic agents. Blood Rev 2010;24:179.
Sargramostim (GM-CSF) Leukine Wolff T et al: Folic acid supplementation for the prevention of neural tube defects:
An update of the evidence for the U.S. Preventive Services Task Force. Ann
Vitamin B 12
Oral, parenteral Generic cyanocobalamin or Intern Med 2009;150:632.
hydroxocobalamin
Nasal Nascobal, CaloMist

C ASE STUD Y ANSWER

This patient’s megaloblastic anemia appears to be due to neurologic damage. Folate supplementation, which can com-
vitamin B (cobalamin) deficiency secondary to inadequate pensate for vitamin B –derived anemia, does not prevent
12
12
dietary B . It is important to measure serum concentrations B -deficiency neurologic damage. To correct this patient’s
12
12
of both folic acid and cobalamin because megaloblastic vitamin B deficiency, she would probably be treated paren-
12
anemia can result from deficiency of either nutrient. It is terally with cobalamin because of her neurologic symptoms,
especially important to diagnose vitamin B deficiency followed by oral supplementation to maintain her body
12
because this deficiency, if untreated, can lead to irreversible stores of vitamin B .
12